The risks and benefits of clozapine versus chlorpromazine

J. Claghorn, G. Honigfeld, F. S. Abuzzahab, R. Wang, R. Steinbook, V. Tuason, G. Klerman

Research output: Contribution to journalArticle

267 Citations (Scopus)

Abstract

Clozapine is an atypical antipsychotic drug with reduced risk of unwanted neurological effects in comparison with other drugs. In this multicenter study, 151 hospitalized schizophrenic patients were randomly assigned to treatment under double-blind conditions to assess the antipsychotic efficacy and safety of clozapine versus chlorpromazine. All patients exhibited tardive dyskinesia or other extrapyramidal side effects associated with at least two prior neuroleptics. Eleven patients were dropped from treatment due to extrapyramidal symptoms while being treated with chlorpromazine; only one clozapine patient's treatment was terminated for this reason. Clozapine patients exhibited clinical improvement superior to that of chlorpromazine patients as assessed by the Brief Psychiatric Rating and Clinical Global Impression scales. These results suggest that clozapine is well tolerated and may be therapeutically superior to chlorpromazine in treating psychotic behavior. Agranulocytosis potential can be minimized by frequent white blood cell counts and removing nonresponding patients from treatment prior to the peak risk period (months 2 through 6).

Original languageEnglish
Pages (from-to)377-384
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume7
Issue number6
StatePublished - Dec 1 1987
Externally publishedYes

Fingerprint

Clozapine
Chlorpromazine
Antipsychotic Agents
Agranulocytosis
Therapeutics
Leukocyte Count
Multicenter Studies
Psychiatry
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Claghorn, J., Honigfeld, G., Abuzzahab, F. S., Wang, R., Steinbook, R., Tuason, V., & Klerman, G. (1987). The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology, 7(6), 377-384.

The risks and benefits of clozapine versus chlorpromazine. / Claghorn, J.; Honigfeld, G.; Abuzzahab, F. S.; Wang, R.; Steinbook, R.; Tuason, V.; Klerman, G.

In: Journal of Clinical Psychopharmacology, Vol. 7, No. 6, 01.12.1987, p. 377-384.

Research output: Contribution to journalArticle

Claghorn, J, Honigfeld, G, Abuzzahab, FS, Wang, R, Steinbook, R, Tuason, V & Klerman, G 1987, 'The risks and benefits of clozapine versus chlorpromazine', Journal of Clinical Psychopharmacology, vol. 7, no. 6, pp. 377-384.
Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V et al. The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology. 1987 Dec 1;7(6):377-384.
Claghorn, J. ; Honigfeld, G. ; Abuzzahab, F. S. ; Wang, R. ; Steinbook, R. ; Tuason, V. ; Klerman, G. / The risks and benefits of clozapine versus chlorpromazine. In: Journal of Clinical Psychopharmacology. 1987 ; Vol. 7, No. 6. pp. 377-384.
@article{3f1b6b7f724f4bf28f9e9d8cb0139706,
title = "The risks and benefits of clozapine versus chlorpromazine",
abstract = "Clozapine is an atypical antipsychotic drug with reduced risk of unwanted neurological effects in comparison with other drugs. In this multicenter study, 151 hospitalized schizophrenic patients were randomly assigned to treatment under double-blind conditions to assess the antipsychotic efficacy and safety of clozapine versus chlorpromazine. All patients exhibited tardive dyskinesia or other extrapyramidal side effects associated with at least two prior neuroleptics. Eleven patients were dropped from treatment due to extrapyramidal symptoms while being treated with chlorpromazine; only one clozapine patient's treatment was terminated for this reason. Clozapine patients exhibited clinical improvement superior to that of chlorpromazine patients as assessed by the Brief Psychiatric Rating and Clinical Global Impression scales. These results suggest that clozapine is well tolerated and may be therapeutically superior to chlorpromazine in treating psychotic behavior. Agranulocytosis potential can be minimized by frequent white blood cell counts and removing nonresponding patients from treatment prior to the peak risk period (months 2 through 6).",
author = "J. Claghorn and G. Honigfeld and Abuzzahab, {F. S.} and R. Wang and R. Steinbook and V. Tuason and G. Klerman",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "7",
pages = "377--384",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The risks and benefits of clozapine versus chlorpromazine

AU - Claghorn, J.

AU - Honigfeld, G.

AU - Abuzzahab, F. S.

AU - Wang, R.

AU - Steinbook, R.

AU - Tuason, V.

AU - Klerman, G.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Clozapine is an atypical antipsychotic drug with reduced risk of unwanted neurological effects in comparison with other drugs. In this multicenter study, 151 hospitalized schizophrenic patients were randomly assigned to treatment under double-blind conditions to assess the antipsychotic efficacy and safety of clozapine versus chlorpromazine. All patients exhibited tardive dyskinesia or other extrapyramidal side effects associated with at least two prior neuroleptics. Eleven patients were dropped from treatment due to extrapyramidal symptoms while being treated with chlorpromazine; only one clozapine patient's treatment was terminated for this reason. Clozapine patients exhibited clinical improvement superior to that of chlorpromazine patients as assessed by the Brief Psychiatric Rating and Clinical Global Impression scales. These results suggest that clozapine is well tolerated and may be therapeutically superior to chlorpromazine in treating psychotic behavior. Agranulocytosis potential can be minimized by frequent white blood cell counts and removing nonresponding patients from treatment prior to the peak risk period (months 2 through 6).

AB - Clozapine is an atypical antipsychotic drug with reduced risk of unwanted neurological effects in comparison with other drugs. In this multicenter study, 151 hospitalized schizophrenic patients were randomly assigned to treatment under double-blind conditions to assess the antipsychotic efficacy and safety of clozapine versus chlorpromazine. All patients exhibited tardive dyskinesia or other extrapyramidal side effects associated with at least two prior neuroleptics. Eleven patients were dropped from treatment due to extrapyramidal symptoms while being treated with chlorpromazine; only one clozapine patient's treatment was terminated for this reason. Clozapine patients exhibited clinical improvement superior to that of chlorpromazine patients as assessed by the Brief Psychiatric Rating and Clinical Global Impression scales. These results suggest that clozapine is well tolerated and may be therapeutically superior to chlorpromazine in treating psychotic behavior. Agranulocytosis potential can be minimized by frequent white blood cell counts and removing nonresponding patients from treatment prior to the peak risk period (months 2 through 6).

UR - http://www.scopus.com/inward/record.url?scp=0023484475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023484475&partnerID=8YFLogxK

M3 - Article

C2 - 3323261

AN - SCOPUS:0023484475

VL - 7

SP - 377

EP - 384

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -